PodParley PodParley
PodParley
Phase I Trial of DOC1021 Cell-Based Immunotherapy for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma - report from SITC 2025 episode artwork

EPISODE · Nov 27, 2025 · 8 MIN

Phase I Trial of DOC1021 Cell-Based Immunotherapy for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma - report from SITC 2025

from Medical Digest & Congress Report · host Medical Congress News

Professor William Decker discusses the Phase I Trial of DOC1021 cell-based immunotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma at SITC's 40th Anniversary Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:phase-i-trial-doc1021-cell-based-immunotherapy-resectable-or-borderline-resectable-pancreatic-ductal-adenocarcinoma

Episode metadata supplied by the publisher feed · Published Nov 27, 2025

Embed this episode

NOW PLAYING

Phase I Trial of DOC1021 Cell-Based Immunotherapy for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma - report from SITC 2025

0:00 8:04

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

The Dawn of Phone-Based Retirement and 2025 Tech Trends

Mar 16, 2026 ·11m

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 8 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on November 27, 2025.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!